A randomized controlled trial on the application of a chronic disease management platform based on digital health technology combined with an innovative model of intelligent management for hypertension in patients with hypertension

547 participants completed the study (Intervention: <i>n</i> = 273; Control: <i>n</i> = 274). The intervention group achieved a greater reduction in SBP at 12 months (adjusted between-group difference: -3.14 mmHg, 95% CI: -5.24 to -1.03, <i>P</i> = 0.004). Subgroup analysis revealed significant heterogeneity by baseline SBP (interaction <i>P</i> < 0.001). For participants with baseline SBP below the median (<146 mmHg), the intervention group achieved a significantly larger SBP reduction (between-group difference: -6.79 mmHg, 95% CI: -9.62 to -3.96). It is expected that a decrease of 5 mmHg can reduce the risk of cardiovascular events by about 10%.